Entropy Technologies LP Acquires 9,979 Shares of Guardant Health, Inc. $GH

Entropy Technologies LP lifted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 140.3% in the fourth quarter, Holdings Channel reports. The fund owned 17,093 shares of the company’s stock after purchasing an additional 9,979 shares during the quarter. Entropy Technologies LP’s holdings in Guardant Health were worth $1,746,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Allworth Financial LP lifted its holdings in shares of Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after acquiring an additional 138 shares during the last quarter. Eastern Bank lifted its holdings in shares of Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC lifted its holdings in shares of Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares during the last quarter. Danske Bank A S lifted its holdings in shares of Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after acquiring an additional 200 shares during the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna lifted its holdings in shares of Guardant Health by 1.9% in the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Down 1.4%

Shares of GH stock opened at $129.82 on Tuesday. The firm has a market cap of $17.21 billion, a price-to-earnings ratio of -38.29 and a beta of 1.61. The company’s 50 day moving average is $104.23 and its 200 day moving average is $102.22. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $135.00.

Insider Activity at Guardant Health

In related news, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares in the company, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 449,238 shares of company stock valued at $51,164,492 over the last quarter. 5.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Guardant Health in a research note on Friday, June 5th. They issued a “buy” rating and a $165.00 price objective for the company. Leerink Partners raised their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Guggenheim downgraded shares of Guardant Health from a “buy” rating to a “buy” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $141.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.